Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2791633 | 0.90 | TAAR1 (0.40) | IDO1NOS3NOS1TACR1TSHR | |
| SCHEMBL2795945 | 0.81 | TAAR1 (0.41) | IDO1NOS3NOS1TACR1TSHR | |
| SCHEMBL2793246 | 0.81 | TAAR1 (0.41) | IDO1NOS3NOS1TACR1TSHR | |
| SCHEMBL2793515 | 0.79 | IDO1 (0.41) | IDO1TACR1TSHRMAPK1TAAR1 | |
| SCHEMBL16215293 | 0.78 | HTR2A (0.40) | IDO1NOS3NOS1TACR1TSHR | |
| SCHEMBL2793814 | 0.77 | TAAR1 (0.43) | IDO1NOS3NOS1TSHRMAPK1 | |
| SCHEMBL806196 | 0.77 | TAAR1 (0.56) | IDO1TSHRMAPK1TAAR1HTR2A | |
| SCHEMBL445763 | 0.75 | TACR1 (0.44) | NOS3NOS1TACR1 | |
| Hydrochloric Acid SCHEMBL23577777 | 0.75 | TAAR1 (0.55) | IDO1TSHRMAPK1TAAR1HTR2A | |
| SCHEMBL12398665 | 0.75 | IDO1 (0.41) | IDO1NOS3NOS1TACR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1921078-B1 | MULTIKINASE INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-01-09 | — | — | EP | disclosed |
| EP-1921078-B1 | MULTIKINASE INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-8299252-B2 | Pyrazolopyridine and pyrrolopyridine multikinase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299252-B2 | Pyrazolopyridine and pyrrolopyridine multikinase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299252-B2 | Pyrazolopyridine and pyrrolopyridine multikinase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100168430-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168430-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168430-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1921078-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168430-A1 | MULTIKINASE INHIBITOR | REN, RAF1, CHUK | IDO1 2346/4885NOS3 1317/4885NOS1 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.